医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s to Release Q3FY16 Results on Feb 9, 2016; Earnings Call Slated for Feb 9, 6:30 PM IST / 8:00 AM EST

2016年01月28日 PM03:06
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Dr. Reddy’s Laboratories (NYSE: RDY; NSE: DRREDDY; BSE: 500124) will announce results for the Third Quarter and 9 months ended December 31, 2015 on Tuesday, February 9, 2016 after the Board Meeting. The results will be available on the Company’s website www.drreddys.com.

Summary of Events

 

Event

   

Date and Time

   

Medium

Release of financial results February 9th, after the Board Meeting

Email, Media, Company website, Business Wire

Earnings Call

February 9th, 6:30 PM IST / 8:00 AM EST

Hosted by the Company (Details below)
Webcast of Earnings Call

February 9th, 6:30 PM IST / 8:00 AM EST through Feb 13th

URL available on Company’s website, www.drreddys.com

Transcript of the Earnings call     Will be available on the Company’s website    

URL available on Company’s website, www.drreddys.com

 

Earnings Call

Following the release, the management of the Company will host an earnings call to discuss the Company’s financial performance. (Dial In and other details given below)

Audio Webcast

The audio webcast of the earnings call will be available to all interested parties at www.drreddys.com. Please visit the web site at least fifteen minutes ahead of the scheduled start time to register and to download and install any necessary audio software. Participants in the webcast can listen to the proceedings, but will not be able to ask questions. The replay will be available 2 hours after the earnings call, through February 13, 2016. For play back dial in phone No: 022 3065 2322, 022 61813322 and ID: 375#.

Transcript

The transcript of the earnings call will also be available on the Company’s website.

 

Conference Dial-In Numbers

Primary Number:    

+91 22 3960 0616

Secondary Number:    

+91 22 6746 5826

The numbers listed above are universally accessible from all networks and all countries.

Local Access Number:

6000 1221

Available in – Ahmedabad, Bangalore, Bhubaneswar, Chandigarh, Chennai, Coimbatore, Delhi, Goa, Guntur, Gurgaon, Hyderabad, Indore, Jamshedpur, Kanpur, Kochi/Cochin, Kolhapur, Kolkata, Nagpur, Noida, Patna, Pune, Raipur, Rajkot, Surat, Trivandrum, Vadodara, Vijayawada

Accessible from all major carriers except BSNL/MTNL.

3940 3977

Available in – Ahmedabad, Bangalore, Chandigarh, Chennai, Gurgaon (NCR), Hyderabad, Kochi/Cochin, Kolkata, Lucknow, Pune
   

Accessible from all carriers.

International Toll Free Number:

USA: 1 866 746 2133

UK: 0 808 101 1573

Singapore: 800 101 2045

   

Hong Kong: 800 964 448

 

No password/pin number is necessary to dial in to any of the other calls. As participation in the call is limited, early registration is encouraged. The operator will provide instructions on asking questions before and during the call.

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (NYSE: RDY NSE: DRREDDY; BSE: 500124) is an integrated pharmaceutical company, committed to accelerating access to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infectives. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, Russia & CIS, Venezuela and India. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation , including related integration issues.

The company assumes no obligation to update any information contained herein.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160127006512/en/

CONTACT

Dr. Reddy’s Laboratories
Investor Relations:
KEDAR
UPADHYE
+91-40-66834297
kedaru@drreddys.com
or
Media
Relations:

CALVIN PRINTER
+91-40-49002121
calvinprinter@drreddys.com

同じカテゴリーの記事 

  • パース・バイオサイエンシズが研究室用自動化プロバイダー・プログラムをローンチし、ハミルトン、オープントロンズ、ラボワークス、SPTラボテックと提携
  • Parse Biosciences与Hamilton、Opentrons Labworks和SPT Labtech合作推出实验室自动化供应商计划
  • Charting New Paths: Mannatech Expanding with Thailand Office, Grand Opening, September 2024
  • Exergen起诉Baxter International,以捍卫其公布口腔体温计准确性数据的权利
  • Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting